Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Revenue (2019 - 2025)

Addex Therapeutics' Revenue history spans 7 years, with the latest figure at $310.29 for Q4 2025.

  • On a quarterly basis, Revenue fell 81.97% to $310.29 in Q4 2025 year-over-year; TTM through Dec 2025 was $101329.0, a 77.9% decrease, with the full-year FY2025 number at $36150.1, down 92.16% from a year prior.
  • Revenue came in at $310.29 for Q4 2025, down from $37158.3 in the prior quarter.
  • The five-year high for Revenue was $1.1 million in Q2 2021, with the low at $310.29 in Q4 2025.
  • Historically, Revenue has averaged $386973.1 across 5 years, with a median of $319268.8 in 2024.
  • Biggest five-year swings in Revenue: surged 2407.84% in 2021 and later plummeted 99.0% in 2024.
  • Year by year, Revenue stood at $431076.6 in 2021, then soared by 42.66% to $614955.3 in 2022, then tumbled by 71.87% to $172993.7 in 2023, then crashed by 99.0% to $1721.4 in 2024, then crashed by 81.97% to $310.29 in 2025.
  • Business Quant data shows Revenue for ADXN at $310.29 in Q4 2025, $37158.3 in Q3 2025, and $1721.4 in Q4 2024.